Hepatocellular carcinoma

Dopazo, Cristina; Søreide, Kjetil; Rangelova, Elena; Mieog, Sven; Carrion-Alvarez, Lucia; Diaz-Nieto, Rafael; Primavesi, Florian; Stättner, Stefan

doi:10.1016/j.ejso.2023.107313

Cited by 19 publications

(2 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intricate interplay between these genetic polymorphisms and environmental risk factors contributes to the complexity of HCC pathogenesis [ 20 – 22 ]. Current treatment options for HCC range from surgical treatment (liver resection and transplantation) and locoregional therapies such as chemoembolization and radiofrequency ablation to systemic therapies including targeted therapy (e.g., sorafenib and lenvatinib) and immunotherapy [ 23 – 27 ]. Although advances in the treatment methods for HCC have improved overall survival (OS), the therapeutic effects of currently available treatments are attenuated over time as disease progresses.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of RNA methylation in hepatocellular carcinoma

Bao,

Zeng,

Lou

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a primary liver malignancy with high mortality rates and poor prognosis. Recent advances in high-throughput sequencing and bioinformatic technologies have greatly enhanced the understanding of the genetic and epigenetic changes in liver cancer. Among these changes, RNA methylation, the most prevalent internal RNA modification, has emerged as a significant contributor of the development and progression of HCC. Growing evidence has reported significantly abnormal levels of RNA methylation and dysregulation of RNA-methylation-related enzymes in HCC tissues and cell lines. These alterations in RNA methylation play a crucial role in the regulation of various genes and signaling pathways involved in HCC, thereby promoting tumor progression. Understanding the pathogenesis of RNA methylation in HCC would help in developing prognostic biomarkers and targeted therapies for HCC. Targeting RNA-methylation-related molecules has shown promising potential in the management of HCC, in terms of developing novel prognostic biomarkers and therapies for HCC. Exploring the clinical application of targeted RNA methylation may provide new insights and approaches for the management of HCC. Further research in this field is warranted to fully understand the functional roles and underlying mechanisms of RNA methylation in HCC. In this review, we described the multifaceted functional roles and potential mechanisms of RNA methylation in HCC. Moreover, the prospects of clinical application of targeted RNA methylation for HCC management are discussed, which may provide the basis for subsequent in-depth research on RNA methylation in HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of RNA methylation in hepatocellular carcinoma

Bao,

Zeng,

Lou

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…Liver transplantation (LT) is so far the only curative option for patients with hepatocellular carcinoma (HCC) and accompanying liver cirrhosis [ 1 ]. HCC represents the most common malignant indication for LT [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy

Rohland,

Freye,

Schwenk

et al. 2024

Cancers

View full text Add to dashboard Cite

Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.

show abstract